Generation Bio (GBIO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 4, 2025, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 3, 2025.
Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2028 annual meeting: Ron Cooper, Anthony Quinn, and Jason Rhodes.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Advisory vote on executive compensation for named executive officers.
Proposal to amend the restated certificate of incorporation to effect a reverse stock split at a ratio between 1-for-10 and 1-for-30, with the board determining the exact ratio and timing.
Proxyholders authorized to vote on other business that may arise at the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and the reverse stock split.
Latest events from Generation Bio
- ctLNP and iqDNA advances enable durable, re-dosable in vivo therapies for major diseases.GBIO
TD Cowen Genetic Medicines & RNA Summit3 Feb 2026 - Redosable genetic medicine platforms advance T cell, HSC, and hemophilia A programs.GBIO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Redosable in vivo gene editing and novel LNPs drive next-gen therapies for blood and liver diseases.GBIO
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Selective ctLNP siRNA delivery to T cells targets autoimmune disease, IND planned for 2H26.GBIO
TD Cowen 45th Annual Healthcare Conference26 Dec 2025 - Up to $600M in securities may be offered, including $237M via ATM sales through TD Cowen.GBIO
Registration Filing16 Dec 2025 - Proxy covers director elections, auditor ratification, say-on-pay, and a reverse stock split.GBIO
Proxy Filing2 Dec 2025 - Proxy seeks approval for director elections, auditor, executive pay, and a reverse stock split.GBIO
Proxy Filing2 Dec 2025 - Selective LNP-siRNA delivery to T-cells targets autoimmune disease with strong preclinical data.GBIO
24th Annual Needham Virtual Healthcare Conference24 Nov 2025 - Selective siRNA delivery to T cells offers new hope for autoimmune disease treatment.GBIO
Jefferies Global Healthcare Conference 202510 Nov 2025